Frühzeitiges Auftreten eines Fingolimod-assoziierten Makulaödems-Reference-Cited by-同舟云学术

Frühzeitiges Auftreten eines Fingolimod-assoziierten Makulaödems

Published:2017-06-26 Issue:5 Volume:115 Page:424-428
ISSN:0941-293X
Container-title:Der Ophthalmologe
language:de
Short-container-title:Ophthalmologe

Author:

Schelenz D.,Kleiter I.,Schöllhammer J.,Rehrmann J.,Elling M.,Dick H. B.,Kakkassery V.

Publisher

Springer Science and Business Media LLC

Subject

Ophthalmology

Link

http://link.springer.com/article/10.1007/s00347-017-0526-7/fulltext.html

Reference11 articles.

1. http://www.ema.europa.eu/docs/de_DE/document_library/EPAR_-_Product_Information/human/002202/WC500104528.pdf . Zugegriffen: 19. Juni 2017.

2. National Institute for Health and Clinical Excellence (2012) Final appraisal determination – Fingolimod for the treatment of highly active relapsing-remitting multiple sclerosis

3. Leitlinien für Diagnostik und Therapie in der Neurologie – Diagnose und Therapie der Multiplen Sklerose. (2015) Deutsche Gesellschaft für Neurologie

4. Ayzenberg I, Hoepner R, Kleiter I (2016) Fingolimod for multiple sclerosis and emerging indications: appropriate patient selection, safety precautions, and special considerations. Ther Clin Risk Manag 12:261–272

5. Aktas O, Ingwersen J, Kieseier B, Kury P, Hohlfeld R, Hartung HP (2011) Oral fingolimod in multiple sclerosis: therapeutic modulation of the sphingosine-1-phosphate system. Nervenarzt 82(2):215–225

Cited by 3 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Diagnosis and Management of Fingolimod-Associated Macular Edema;Frontiers in Neurology;2022-07-15

2. Disorders of vision in multiple sclerosis;Clinical and Experimental Optometry;2021-08-04

3. Fingolimod;Reactions Weekly;2019-08